Cyclical etidronate therapy for prevention of postmenopausal bone loss: A 1-year open-label follow-up study

Calcified Tissue International

Volumn 66, Issue 5, 2000, Pages 348-354

  Fogelman, I ^a   Herd, R J M ^a   Blake, G M ^a   Balena, R ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Bone mineral measurements; Cyclical etidronate therapy; Treatment withdrawal

Indexed keywords

CALCIUM; ETIDRONIC ACID;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FEMUR; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; TRABECULAR BONE;

AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; SPINE; TIME FACTORS;

EID: 0034001591     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002230010072     Document Type: Article

References (24)

1. Bell NH, Johnson RH (1997) Bisphosphonates in the treatment of osteoporosis. Endocrine 6:203-206
2. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:3288-3298
3. Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA (1986) Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 24:57-62
4. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85
5. Yates AJ, Rodan GA (1998) Alendronate and osteoporosis. Drug Discoveries Today 3:69-78
6. Plosker GL, Goa KL (1994) Clodronate. Drugs 47:945-982
7. Kahn SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MNC, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG (1997) Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700-1707
8. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S (1994) Long-term effects of a treatment course with oral alendronate for postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837
9. Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collete J, Franchimont P (1989) Prevention of postmenopausal bone loss by tiludronate. Lancet ii:1469-1471
10. Stock JL, Bell NH, Chestnut CH, Ensrud KE, Genant HK, Harris ST, McClung MR (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate. Am J Med 103:291-297
11. Landman JO, Hammdy NA, Pauwels EKJ, Papapoulos SE (1995) Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80:3465-3468
12. Hosking D, Clair ED, Chilvers CE. Christiansen C, Ravn P, Wasnich RD (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485-492
13. Mortensen L, Charles P, Bekker P, Digennaro J, Johnston CC (1998) Prevention of early postmenopausal bone loss by risedronate: a two-year study. J Clin Endocrinol Metab 83:396-402
14. Heath DA, Bullivant BG, Webber D, Pack S, Balena R (1996) Effects of cyclical etidronate therapy in the prevention of bone loss in early postmenopausal women. J Bone Miner Res 11(suppl 1):S342
15. Herd RJM, Balena R, Blake GM, Ryan PJ, Fogelman I (1997) The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year double-blind, placebo-controlled study. Am J Med 103:92-99
16. Pouilles JM, Tremollieres F, Roux C, Sebert JL, Alexandre C, Goldberg D (1997) Effects of cyclical etidronate on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporosis Int 7:213-218
17. Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R (1997) Prevention of early postmenopausal bone loss with cyclical etidronate therapy: a double-blind, placebo-controlled study and 1 year follow-up. J Clin Endocrinol Metab 82:2784-2791
18. Wimalawansa SJ (1995) Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomised study. Am J Med 99:36-42
19. Blake GM, Preston NG, Patel R, Herd RJM, Fogelman I (1999) An unexpected change in DXA calibration not detected by routine quality control checks. Osteoporosis Int 9:115-120
20. Parfitt AM (1996) Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis. Osteoporosis :315-327
21. El Hajj-Fuleihan G, Luckey M, Bauer R, Wasnich R, Krupa D, Reda C, Yates AJ, Daifotis A (1997) Effects of discontinuation of alendronate in early postmenopausal women. J Bone Miner Res 12(suppl 1):S143
22. Ravn P, Christensen J, Clemmesen B, Riis BJ, Christiansen C (1996) The effect on bone mass and bone markers of ibandronate treatment in postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled, dose-finding study with 1-year follow-up. J Bone Miner Res 11(suppl 1):S345
23. Kasting GB, Francis MD (1992) Retention of etidronate in human, dog and rat. J Bone Miner Res 7:513-522
24. King LE, Grynpas MD, Tomlinson G, Vieth R (1997) Pamidronate content and turnover in sternum, vertebral body and iliac bone biopsies. Bone 20:405-411